Follow-The-Filings

Security · featured owners

HALO Halozyme Therapeutics

Health Care COM Equity as of 2026 Q2 among managers we track

  • 2 Owners
  • Max 0.4%
  • $3M
  • 1 add

HALO (Halozyme Therapeutics) is held in 2 featured 13F books as of 2026 Q2. Torray Investment Partners is the largest tracked holder by portfolio weight (0.41%). Figures are as-filed 13F, not free float.

Who owns this now

Largest portfolio weights among featured holders · max 0.4% (Torray Investment Partners) · not free-float ownership

  1. Torray Investment Partners add 0.41%

holders

sorted by value · long equity only · current book 2026 Q2 · open a manager for their book

history
Torray Investment Partners 2026 Q2 0.41% Add +1.4% 38,703 $3M history
Richard Pzena - Pzena Investment Management 2026 Q2 <0.01% Hold 4,049 $317K history

2 current · options excluded

SEC filings

Recent issuer filings from EDGAR · 11 shown · open Filing / Doc on SEC.gov

Filed Form Detail Links
8-K 5.02 Filing Doc
8-K 2.02,9.01 Filing Doc
10-Q Filing Doc
8-K 5.02 Filing Doc
8-K 2.02,9.01 Filing Doc
10-Q Filing Doc
8-K 5.07 Filing Doc
8-K 5.02,9.01 Filing Doc
8-K 5.03,9.01 Filing Doc
DEFA14A Filing Doc
8-K 5.02,9.01 Filing Doc

Insider forms

Form 3 / 4 / 5 from EDGAR · 18 rows shown

Filed Form Detail Links
4 Period Sep 9, 2026 Filing Doc
4 Period Sep 1, 2026 Filing Doc
4 Period Aug 17, 2026 Filing Doc
4 Period Aug 10, 2026 Filing Doc
4 Period Jul 8, 2026 Filing Doc
4 Period Jul 1, 2026 · 2 forms Filing Doc
4 Period Jun 30, 2026 Filing Doc
4 Period Jun 29, 2026 Filing Doc
4 Period Jun 12, 2026 Filing Doc
4 Period Jun 1, 2026 Filing Doc
4 Period Jun 1, 2026 Filing Doc
4 Period May 11, 2026 Filing Doc
4 Period May 5, 2026 · 6 forms Filing Doc
4 Period May 1, 2026 Filing Doc
4 Period Apr 6, 2026 Filing Doc
4 Period Apr 1, 2026 · 2 forms Filing Doc
4 Period Mar 9, 2026 Filing Doc
4 Period Mar 2, 2026 Filing Doc

Updated 4 days ago Source: SEC EDGAR submissions All on EDGAR

financials

US-GAAP annual · as tagged in Form 10-K · fiscal years · values link to the SEC filing

Income statement

Metric FY2023 FY2024 FY2025
Revenue $0.829B $1.02B $1.4B
Gross profit * $0.637B $0.856B $1.17B
Gross margin * 76.8% 84.3% 83.6%
Net income $281.59M $444.09M $316.89M
Net margin * 34.0% 43.7% 22.7%

Balance sheet

Metric FY2023 FY2024 FY2025
Total current assets $0.746B $1.09B $0.825B
Total non-current assets * $0.987B $0.978B $1.7B
Total assets $1.73B $2.06B $2.53B
Total current liabilities $112.49M $139.1M $177.09M
Total non-current liabilities * $1.54B $1.56B $2.3B
Total equity $83.81M $363.82M $48.81M

Cash flow

Metric FY2023 FY2024 FY2025
Cash from operations $388.57M $479.06M $651.56M
Cash from investing -$96.91M -$262.72M -$545.81M
Cash from financing -$407.99M -$218.86M -$85.17M
Net change in cash -$116.32M -$2.52M $20.57M

Source: SEC companyfacts (US-GAAP 10-K) · * = computed (not a single XBRL tag) · fiscal year as labeled by the issuer · not adjusted or audited by Follow-The-Filings

ownership over time

filing count by report period · click a bar for that quarter’s holders